Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system.

PURPOSE Mucositis occurs in almost all patients treated with radiotherapy for head and neck cancer. The aim of this multicenter, double-blind, prospective, randomized trial was to evaluate the clinical efficacy of an economically viable antimicrobial lozenge (bacitracin, clotrimazole, and gentamicin [BcoG]) in the alleviation of radiation-induced mucositis in patients with head and neck cancer. PATIENTS AND METHODS One hundred thirty-seven eligible patients were randomized to treatment with either antimicrobial lozenge (69 patients) or placebo lozenge (68 patients). The primary end point of the study was the time to development of severe mucositis from the start of radiotherapy. Secondary end points included severity and duration of mucositis, pain measurement, radiation therapy interruption, and quality of life. Mucositis was scored using a validated mucositis scoring system. RESULTS Toxicity profiles were similar between the two arms of the study. The median time to development of severe mucositis from the start of radiotherapy was 3.61 weeks on BCoG and 3.96 weeks on placebo (P =.61). There were no statistically significant differences between the arms in the extent of severe mucositis as measured by physician, in oral toxicities as recorded by patients, or in radiotherapy delays. CONCLUSION This study was conducted on the basis of a pilot study that demonstrated the BCoG lozenge to be tolerable and microbiologically efficacious. A validated mucositis scoring system was used. However, in this group of patients treated with conventional radiotherapy, the lozenge did not impact significantly on the severity of mucositis. Whether such a lozenge would be beneficial in treatment situations where rate of severe mucositis is higher (ie, in patients treated with unconventional fractionation or with concomitant chemotherapy) is unknown.

[1]  J. Epstein,et al.  A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy , 2002, Head & neck.

[2]  P. Levendag,et al.  Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study. , 2001, International journal of radiation oncology, biology, physics.

[3]  J. Epstein,et al.  Quality of life and oral function in patients treated with radiation therapy for head and neck cancer , 2001, Head & neck.

[4]  F. Spijkervet,et al.  Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Calais,et al.  Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx Carcinoma. , 1999, Journal of the National Cancer Institute.

[6]  F. Spijkervet,et al.  Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy , 1999, Cancer.

[7]  H. Safran,et al.  Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study. , 1999, Seminars in radiation oncology.

[8]  D. McGuire,et al.  Acute oral pain and mucositis in bone marrow transplant and leukemia patients: data from a pilot study. , 1998, Cancer nursing.

[9]  M. Vincent,et al.  Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. , 1998, Oral oncology.

[10]  A. Berger,et al.  Factors influencing oral cavity status during high-dose antineoplastic therapy: a secondary data analysis. , 1998, Oncology nursing forum.

[11]  T. Wendt,et al.  Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Tuason,et al.  A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results , 1997, Head & neck.

[13]  B. Jeremic,et al.  Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  C. C. Wang,et al.  Role of accelerated fractionated irradiation for supraglottic carcinoma: assessment of results. , 1997, The cancer journal from Scientific American.

[15]  J. Paul,et al.  The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. , 1996, British Journal of Cancer.

[16]  V. Vitale,et al.  Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. , 1996, Journal of the National Cancer Institute.

[17]  N. Nelson,et al.  Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Kligerman,et al.  Decreased acute toxicity by using midline mucosa-sparing blocks during radiation therapy for carcinoma of the oral cavity, oropharynx, and nasopharynx. , 1995, Radiology.

[19]  P. François,et al.  Hyperfractionation in the reirradiation of head and neck cancers. Result of a pilot study , 1995 .

[20]  L. Nardone,et al.  Prolonged Continuous Infusion of Carboplatin and Concomitant Radiotherapy in Advanced Head and Neck Cancer: A Phase I Study , 1995, American journal of clinical oncology.

[21]  J. O'fallon,et al.  Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Paccagnella,et al.  A Pilot Study of Concomitant Radiation and Chemotherapy in Patients with Locally Advanced Head and Neck Cancer , 1993, American journal of clinical oncology.

[23]  J. Epstein,et al.  Radiation therapy and pain in patients with head and neck cancer. , 1993, European journal of cancer. Part B, Oral oncology.

[24]  J. Epstein,et al.  Management of orofacial pain in cancer patients. , 1993, European journal of cancer. Part B, Oral oncology.

[25]  S Schraub,et al.  Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  W. Panje,et al.  Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. , 1992, Journal of the National Cancer Institute.

[27]  D. Reece,et al.  Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. , 1992, Oral surgery, oral medicine, and oral pathology.

[28]  W. Fegeler,et al.  Effect of selective flora suppression on colonization, infection, and mortality in critically ill patients: A one‐year, prospective consecutive study , 1991, Critical care medicine.

[29]  F. Spijkervet,et al.  Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients , 1991, Journal of surgical oncology.

[30]  F. Spijkervet,et al.  Mucositis prevention by selective elimination of oral flora in irradiated head and neck cancer patients. , 1990, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[31]  W. Curran,et al.  Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long‐term results of the radiation therapy oncology group study 81‐17 , 1990, Cancer.

[32]  F. Spijkervet,et al.  Chlorhexidine inactivation by saliva. , 1990, Oral surgery, oral medicine, and oral pathology.

[33]  G. Ferretti,et al.  Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis: a randomized double-blind trial. , 1990, Oral surgery, oral medicine, and oral pathology.

[34]  Y. Wahlin.  Effects of chlorhexidine mouthrinse on oral health in patients with acute leukemia. , 1989, Oral surgery, oral medicine, and oral pathology.

[35]  F. Spijkervet,et al.  Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. , 1989, Oral surgery, oral medicine, and oral pathology.

[36]  Satyandra K. Gupta,et al.  Twice a day versus once a day radiation therapy in head and neck cancer , 1989 .

[37]  W. Woods,et al.  Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouth rinse. , 1989, Bone marrow transplantation.

[38]  G. Ferretti,et al.  Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. , 1988, Bone marrow transplantation.

[39]  C. C. Wang,et al.  Local control of oropharyngeal carcinoma after two accelerated hyperfractionation radiation therapy schemes. , 1988, International journal of radiation oncology, biology, physics.

[40]  W. Mendenhall,et al.  Hyperfractionation for head and neck cancer. , 1988, International journal of radiation oncology, biology, physics.

[41]  I. P. Hunter,et al.  The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic irradiation. , 1988, Clinical radiology.

[42]  G. Ferretti,et al.  Therapeutic use of chlorhexidine in bone marrow transplant patients: case studies. , 1987, Oral surgery, oral medicine, and oral pathology.

[43]  R. Bucknall,et al.  The effects of sub-lethal concentrations of chlorhexidine on bacterial pathogenicity. , 1986, The Journal of hospital infection.

[44]  W. Lee,et al.  Candida infections in patients with acute leukemia: Ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis , 1982, Cancer.

[45]  D. Baker,et al.  The radiobiological basis for tissue reactions in the oral cavity following therapeutic x-irradiation. A review. , 1982, Archives of otolaryngology.

[46]  G. Bodey,et al.  Antibiotic prophylaxis in cancer patients: regimens of oral, nonabsorbable antibiotics for prevention of infection during induction of remission. , 1981, Reviews of infectious diseases.

[47]  F. Bova,et al.  A re-evaluation of split-course technique for squamous cell carcinoma of the head and neck. , 1980, International journal of radiation oncology, biology, physics.

[48]  J. Bennett.  Oral care of cancer patients undergoing head and neck irradiation. , 1979, Dental hygiene.

[49]  M. Cooperstock.  Inactivation of Endotoxin by Polymyxin B , 1974, Antimicrobial Agents and Chemotherapy.

[50]  R. Davies,et al.  The effect of chlorhexidine mouthrinses on the human oral flora. , 1970, Journal of periodontal research.